Pharmanovia
- Catumaxomab Received a Positive Opinion From the EMA's Committee for Medicinal Products for Human Use (CHMP) at Its October 2024 Meeting and If Approved Catumaxomab Will Be the Only Approved Drug Treatment of Malignant Ascites
- Pharmanovia Will Lead All Activities to Launch Catumaxomab
- This Is Pharmanovia's First Monoclonal Antibody and Signifies Our Continued Evolution Into Specialty Pharmaceuticals
BASILDON, England--BUSINESS WIRE--
Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines, has today announced the expansion of its oncology portfolio with a new licensing agreement for catumaxomab, for the treatment of malignant ascites.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).
